IGF1 and acromegaly: Two acromegaly phase 2 trials that incorporated the information and conclusions from the Phase 1 trial have recently been completed: ACROBAT EDGE, which evaluated the safety and efficacy of paltusotine in acromegaly patients whose IGF-1 concentrations were reduced but did not achieve normalization by octreotide or lanreotide depots (NCT0389656), and ACROBAT EVOLVE, which evaluated the safety and efficacy of paltusotine in acromegaly patients whose IGF-1 concentrations were reduced and achieved normalization by octreotide or lanreotide (NCT03792555) [38, 39].